Hoth Therapeutics has shared phase 2 results on its treatment of EGFR inhibitor-induced skin toxicities, ticking off another ...

Hoth Therapeutics reported interim trial results showing all patients improved by Week 6, with reduced disease severity, ...

With May the Fourth waiting in the (Starfighter) wings, do keep your eyes peeled for all the new Star Wars releases at Disney Store — after all, to quote our favorite green Jedi Grand Master, when it ...

(RTTNews) - Hoth Therapeutics (HOTH) announced its collaboration with OnTargetx R&D to advance research for its cancer-fighting therapeutic, HT-KIT. The study focuses on: development and optimization ...

The China National Intellectual Property Administration approved the patent covering Hoth’s HT-KIT technology, which is designed to induce apoptosis (programmed cell death) in cancer cells by ...

Shares of Hoth Therapeutics Inc (NASDAQ:HOTH) advanced 3.6% in premarket trading on Wednesday after the clinical-stage ...

Investing.com -- Hoth Therapeutics Inc (NASDAQ:HOTH) stock rose 5.7% in Thursday premarket trading following the company’s ...

Development and optimization of staining methods for (c-Kit) markers, a critical target in HT-KIT therapeutic mechanism. Processing and qualitative evaluation of tissue samples by a board-certified ...

Hoth Therapeutics, Inc.(NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing therapies for serious and underserved conditions, today announced it has achieved a major European ...

NEW YORK, Dec. 1, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a patient focused biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at ...